Cancer Cells Hijack Centromere Proteins to Keep Telomeres Alive
ALT cancers insert centromeric DNA at telomeres, forming protective chromatin that sustains tumor survival without telomerase.
Summary
Alternative lengthening of telomeres (ALT) is a telomerase-independent survival mechanism used by roughly 5–10% of cancers. Researchers discovered that ALT cancer cells and pediatric neuroblastomas insert centromeric α-satellite DNA and CENP-B sequences directly into telomeric regions. These insertions recruit CENP-A, a centromere-specific histone, forming discrete chromatin 'footprints' at telomeres. This process is driven by epigenetic disruption — particularly loss of ATRX and reduced DNA methylation. When the researchers blocked CENP-A deposition via HJURP inhibition, telomere integrity collapsed and aberrant DNA synthesis occurred during mitosis. The findings reveal an unexpected molecular crosstalk between centromeric and telomeric chromatin in ALT cancers, suggesting a new therapeutic vulnerability.
Detailed Summary
Telomeres protect chromosome ends from degradation, and most cancer cells maintain them using the enzyme telomerase. However, roughly 5–10% of cancers — including aggressive pediatric tumors like neuroblastoma — use an alternative mechanism called ALT (alternative lengthening of telomeres). Understanding how ALT works at the molecular level is critical to developing targeted therapies for these difficult-to-treat cancers.
Researchers from the University of Pittsburgh, the Salk Institute, and collaborating centers examined the genomic and epigenetic landscape of ALT cancer cell lines and primary pediatric neuroblastoma samples. Using long-read sequencing combined with directed methylation mapping (DiMeLo-seq), they identified insertion of centromeric α-satellite repeats and CENP-B box sequences directly into telomeric regions — a highly unusual and previously unreported rearrangement.
These centromeric insertions serve as landing pads for CENP-A, a histone H3 variant normally found only at centromeres. The result is discrete 'centromeric footprints' assembled on telomeres of specific chromosomal subsets. The team showed that this epigenetic reprogramming is initiated by ATRX loss and DNA hypomethylation — hallmarks of ALT activation — which permissively allow centromeric chromatin to form in an otherwise inappropriate chromosomal location.
Functionally, these centromeric footprints are not merely passengers. When the researchers disrupted HJURP, the chaperone responsible for depositing CENP-A, telomere integrity was compromised. ALT activity declined and aberrant telomeric mitotic DNA synthesis (MiDAS) was triggered — a sign of replication stress and genomic instability. This indicates that the centromeric chromatin has been co-opted to stabilize telomeres in ALT cells.
The study proposes that centromeric insertions at telomeres originated through illegitimate recombination but were subsequently selected for because they confer a survival advantage in ALT cancers. HJURP and CENP-A deposition represent potential therapeutic targets, especially in pediatric cancers with ATRX mutations and ALT activation.
Key Findings
- ALT cancers insert centromeric α-satellite DNA and CENP-B boxes into telomeric regions, a novel pathological rearrangement.
- DiMeLo-seq revealed discrete CENP-A chromatin footprints assembled at telomeres on chromosome subsets in ALT cells.
- ATRX loss and DNA hypomethylation drive acquisition of centromeric chromatin signatures at telomeres.
- Blocking HJURP-mediated CENP-A deposition disrupts telomere integrity and triggers aberrant mitotic DNA synthesis.
- Centromeric insertions, though arising by illegitimate recombination, are functionally maintained to support ALT cancer survival.
Methodology
The study combined DiMeLo-seq (directed methylation with long-read sequencing) with genomic analysis of ALT cancer cell lines and primary pediatric neuroblastoma samples. Researchers modeled ALT activation to establish causal links between ATRX loss, DNA hypomethylation, and centromeric chromatin acquisition. Functional experiments used HJURP inhibition to assess the role of CENP-A deposition in telomere stability.
Study Limitations
The study relies primarily on cell lines and a limited set of primary neuroblastoma samples, which may not fully represent ALT tumor heterogeneity. Causal directionality of centromeric insertions — whether they are strictly required for ALT or merely supportive — requires further validation. Long-read sequencing methods like DiMeLo-seq are powerful but still technically demanding and not yet standard in clinical genomics.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: